Subsequent Event (Notes)

3 Months Ended

Mar. 31, 2019

Subsequent Event [Line Items]

Subsequent Events [Text Block]

8.      Subsequent Event

On April 26, 2019, Zynquista™ (sotagliflozin) was approved in the European Union for use as an adjunct to

insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index 27 kg/m2, who

could not achieve adequate glycemic control despite optimal insulin therapy. Upon this approval, the Company is required to make certain royalty payments to JDRF, totaling $4.5 million, which become payable in three equal installments of $1.5 million each, following approval and the first and second anniversaries of such approval. The royalty payments represent consideration for JDRF’s past funding provided to the company for sotagliflozin’s development in type 1 diabetes.